The Impact of Fast Antimicrobial Sensitivity Testing Tools on Stewardship Antibiotic and Clinical Outcome (ACT-FAST)
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorIstituto Clinico Humanitas
About this trial
The ACT-FAST study aims to compare commercially available Rapid Antimicrobial Susceptibility Testing (R-AST) tools with the current standard of care for patients with Bloodstream Infections (BSI). The primary objective is to evaluate whether "early targeted" antibiotic prescriptions, guided by these rapid tests, can improve antimicrobial stewardship and patient clinical outcomes.
To facilitate the evaluation of various diagnostic tools-including those currently on the market and those emerging in the near future-this study utilizes an adaptive clinical trial platform. This flexible design allows for the continuous assessment of different R-AST technologies within a single master protocol, ensuring that the most effective diagnostic strategies are identified efficiently.
Eligibility criteria
Qualifiers
Patients admitted to emergency department or hospitalized for any cause in participating hospitals with clinically suspected BSI and positive blood culture.
At least 18 years of age.
Disqualifiers
Have previously taken part in this trial.
Concurrently participating in the active phase of a study considered incompatible.
Patient with severe or terminal disease with life expectancy shorter than 48 h.
Have an existing directive to withhold life-sustaining treatment, in relation to antibiotic use.
Trial design
Treatments tested in this trial
- Diagnostic Test: Rapid Antimicrobial Susceptibility Testing (R-AST) guided Stewardship
- Standard of Care (SOC)
Treatment groups
400 Participants
are divided into 2 treatment groupsSponsors and collaborators
Istituto Clinico Humanitas
Lead sponsor
BioMérieux
Collaborator
Source ClinicalTrials.gov